Stiripentol
Other Antiepileptics
Sold as Diacomit
- Drug class
- Other Antiepileptics
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 24
Overview
Stiripentol is an active pharmaceutical ingredient in the Other Antiepileptics group (N03AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 20 | May 29, 2026 |
| EU European Union | EMA | 1 | October 20, 2025 |
| CA Canada | Health Canada | 3 | May 27, 2026 |
GBUnited Kingdom· MHRA
20 products
Uses
Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with Dravet’s syndrome (DS) whose seizures are not adequately controlled with clobazam and valproate.
How to take
EUEuropean Union· EMA
1 product
Uses
Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate.
How to take
CACanada· Health Canada
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Stiripentol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 524. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB046370007 · revised May 1, 2026
- [2]European Medicines Agency · EMEA/H/C/000664 · revised October 20, 2025
- [3]Health Canada (DPD) · 02398958 · revised May 27, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.